# Effects of Oral Sildenafil on Mortality in Adults With PAH

> **NCT02060487** · PHASE4 · TERMINATED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 385 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** sildenafil citrate
- **DRUG:** sildenafil citrate
- **DRUG:** sildenafil citrate

## Key facts

- **NCT ID:** NCT02060487
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09-22
- **Primary completion:** 2021-02-26
- **Final completion:** 2021-02-26
- **Target enrollment:** 385 (ACTUAL)
- **Why stopped:** Study was terminated by Sponsor at recommendation of Data Monitoring Committee after completion of first interim analysis as primary objective was met.
- **Last updated:** 2022-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02060487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02060487, "Effects of Oral Sildenafil on Mortality in Adults With PAH". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02060487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*